Value Investor
Start free

Vor Biopharma

VOR on Nasdaq. Biological products, (no diagnostic substances). Market value $1.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-13.0%low

For every $100 of what the whole company costs, it produced $-13.00 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-70.0%five-year median

Each dollar kept in the business earns -70 cents a year. Above 10 is good.

Quality score: 20 of 100. Price score: 33 of 100. Our list needs 70 on quality and 60 on price.

$18.31 a share, 182% above its 1-year low

Over the past year the price has ranged from $6.50 to $35.82.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
2021202220232024202512 monthsto Jun '26
Revenue
n/an/an/an/an/a
Operating margin
n/an/an/an/an/a
Debt to equity
0.000.000.000.00n/a
Shares outstanding
0.04bn0.07bn0.07bn0.01bn0.06bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 53% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $63 million, compared with a loss of $1.6 billion a year ago.
  • Over the past 12 months it spent $141 million more cash than it brought in, compared with $114 million a year earlier.
  • 767% more shares than a year ago. Each share owns a bit less of the company.
  • It has $108 million more cash than debt, down from $191 million a year ago.
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$28m
December 2024-$31m
March 2025-$32m
June 2025-$1.6bn
September 2025-$813m
December 2025$1.7bn
March 2026-$220m
June 2026-$63m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
30 March 2026
Next quarterly (estimated, 10-Q)
10 November 2026

Who owns it

1 long-term investor we follow owns it, down from 2 last quarter. 102 funds in all.

Jun '25
Dec '25
Jun '26

Sold out this quarter

Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

13 investors own more than 5%.

  • at least 19.9%0.0 pts
    (filed with 3 related holders)
    Since 16 July 2026
    What they said

    Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.

    Read the filing
  • Reprogrammed Interchange LLC
    Passive investor
    at least 17.6%−1.0 pts
    (filed with 1 related holder)
    Since 15 October 2025
    What they said

    Item 4 of Schedule 13D is hereby amended and supplemented as follows: From October 15, 2025 through October 16, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of…

    Read the filing
  • FMR LLC
    Passive investor
    at least 12.0%+2.9 pts
    (filed with 1 related holder)
    Since 31 July 2026
  • Chen Yu
    Passive investor
    at least 10.5%
    (filed with 4 related holders)
    Since 30 March 2026
  • ForGrowth III PA B.V.
    Passive investor
    at least 10.0%0.0 pts
    (filed with 2 related holders)
    Since 18 December 2025
    What they said

    The Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business. On December 18, 2025, Wouter Joustra, a General Partner at Forbion Capital, was appointed to the Issuer's board of directors. The Reporting Persons, either directly…

    Read the filing
  • Venrock Healthcare Capital Partners III, L.P.
    Passive investor
    at least 9.9%0.0 pts
    (filed with 6 related holders)
    Since 30 June 2026
  • Verve Capital Limited
    Passive investor
    6.3%−3.0 pts
    Since 30 June 2026
  • BlackRock, Inc.
    Passive investor
    5.7%
    Since 30 June 2026
  • at least 4.5%−4.1 pts
    (filed with 3 related holders)
    Since 31 December 2025
  • Frazier Life Sciences Public Fund, L.P.
    Passive investor
    at least 4.2%−1.6 pts
    (filed with 5 related holders)
    Since 30 June 2026
  • Andrew J. Schwab
    Passive investor
    at least 3.5%
    (filed with 5 related holders)
    Since 8 July 2025
  • at least 3.3%−2.3 pts
    (filed with 2 related holders)
    Since 31 December 2025
  • Qiming Venture Partners VIII-HC, L.P.
    Passive investor
    at least 2.0%−0.8 pts
    (filed with 3 related holders)
    Since 31 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 1 sold $83m.

  • Shah Rajeev M.
    Director
    Sold
    Date
    22 April 2026
    Shares
    165,150
    Price
    $15.77
    Value
    $3m
  • RA CAPITAL MANAGEMENT, L.P.
    Director
    Sold
    Date
    20 April 2026
    Shares
    171,963
    Price
    $15.77
    Value
    $3m
  • RA CAPITAL MANAGEMENT, L.P.
    Director
    Sold
    Date
    17 April 2026
    Shares
    458,411
    Price
    $16.28
    Value
    $7m
  • RA CAPITAL MANAGEMENT, L.P.
    Director
    Sold
    Date
    15 April 2026
    Shares
    53,644
    Price
    $16.01
    Value
    $858,840
  • RA CAPITAL MANAGEMENT, L.P.
    Director
    Sold
    Date
    14 April 2026
    Shares
    153,735
    Price
    $15.97
    Value
    $2m
  • RA CAPITAL MANAGEMENT, L.P.
    Director
    Sold
    Date
    13 April 2026
    Shares
    530,610
    Price
    $16.15
    Value
    $9m
  • Shah Rajeev M.
    Director
    Sold
    Date
    10 April 2026
    Shares
    828
    Price
    $15.75
    Value
    $13,041
  • Shah Rajeev M.
    Director
    Sold
    Date
    9 April 2026
    Shares
    135,201
    Price
    $16.59
    Value
    $2m
  • Shah Rajeev M.
    Director
    Sold
    Date
    8 April 2026
    Shares
    484,104
    Price
    $16.48
    Value
    $8m
  • Kolchinsky Peter
    Director
    Sold
    Date
    6 April 2026
    Shares
    589,257
    Price
    $16.59
    Value
    $10m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

  • It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.